Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
156 hedge funds and large institutions have $402M invested in Intercept Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 59 increasing their positions, 38 reducing their positions, and 18 closing their positions.
94% more call options, than puts
Call options by funds: $43.8M | Put options by funds: $22.5M
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
55% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 38
20% more capital invested
Capital invested by funds: $336M → $402M (+$66.6M)
8% more funds holding
Funds holding: 144 → 156 (+12)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.1M |
| 2 |
Millennium Management
New York
|
+$13.6M |
| 3 |
Renaissance Technologies
New York
|
+$5.57M |
| 4 |
Jane Street
New York
|
+$4.68M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.84M |
| 3 |
Morgan Stanley
New York
|
-$2.63M |
| 4 |
JP Morgan Chase
New York
|
-$2.43M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.28M |
ICPT Hedge Fund Activity: Q3 2022 in Review
156 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2022, worth a combined $402M — up 20% from $336M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ICPT positions and 18 closed out — a net gain of 13 holders — while 59 added to existing stakes and 38 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $23.1M. The largest seller was Fidelity Investments, cutting an estimated $18.2M.
- 156 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2022, up from 144 in Q2 2022.
- Funds reported $402M of Intercept Pharmaceuticals, Inc. stock for Q3 2022, up 20% quarter-over-quarter.
- 31 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2022 and 18 closed out, a net change of +13 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2022 was Point72 Asset Management, an estimated $23.1M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2022 was Fidelity Investments, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2022.